GlassScriptPhysician profile
Obiamaka N Mora
NPI 1124280524
$3,448.62
in general payments reported to CMS, 2019-2025
39 companies · $304 in 2025
The $304 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $570 · 2020: $560 · 2021: $603 · 2022: $652 · 2023: $319 · 2024: $441 · 2025: $304.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,064.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,063.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $561.44 | 2019-2023 | |
| Astellas Pharma US INC | $522.76 | 2019-2025 | Veozah |
| Aspira Women'S Health INC | $190.36 | 2019-2022 | |
| Therapeuticsmd, INC. | $178.36 | 2019-2022 | |
| Mayne Pharma Commercial LLC | $142.51 | 2022-2025 | |
| Amag Pharmaceuticals, INC. | $137.17 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $134.51 | 2019-2025 | |
| Millicent US INC | $130.21 | 2020-2025 | Intrarosa, Femlyv |
| Novartis Pharmaceuticals Corporation | $125.00 | 2019 | |
| Shield Therapeutics INC | $108.76 | 2023-2025 | Accrufer |
| Pfizer INC. | $102.39 | 2019-2024 | |
| Hologic Sales and Service, LLC | $97.94 | 2020-2024 | Aptima, Acessa Provu System |
| Axonics, INC. | $87.98 | 2020 | |
| Avanos Medical | $83.69 | 2020-2024 | On-Q* Pump and Accessories |
| Scynexis, INC. | $80.15 | 2022 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $76.18 | 2024-2025 | Interstim |
| Sumitomo Pharma America, INC. | $71.48 | 2023-2025 | Myfembree, Gemtesa |
| Myovant Sciences INC. | $60.03 | 2021-2022 | |
| Smith+Nephew, INC. | $48.42 | 2024 | Stravix, Grafix |
| Caldera Medical, INC | $47.73 | 2023 | Desara |
| Avion Pharmaceuticals | $47.55 | 2019-2023 | Balcoltra |
| Baxter Healthcare | $46.97 | 2024-2025 | Perclot |
| Evofem Biosciences, INC. | $33.59 | 2021-2022 | |
| Coopersurgical, INC. | $31.36 | 2019-2023 | Mara Console |
| Stryker Corporation | $30.38 | 2020 | |
| Merck Sharp & Dohme LLC | $29.23 | 2021-2024 | Gardasil, Gardasil 9 |
| Acessa Health INC. | $29.17 | 2020-2021 | |
| Mycovia Pharmaceuticals, INC. | $27.90 | 2023 | Vivjoa |
| Exact Sciences Corporation | $22.57 | 2025 | The Cologuard Plus Collection Kit |
| Agile Therapeutics, INC. | $20.98 | 2021 | |
| Duchesnay USA Incorporated | $19.78 | 2019 | |
| Boston Scientific Corporation | $19.40 | 2024 | Obtryx System - Curved |
| Exeltis, USA INC. | $18.36 | 2020 | |
| Lupin INC. | $17.60 | 2020 | |
| Mimedx Group, INC. | $15.20 | 2024 | |
| Gilead Sciences, INC. | $15.08 | 2019 | |
| Daiichi Sankyo INC. | $12.47 | 2019 | |
| Dysis Medical, INC. | $12.36 | 2020 | |
| Teleflex LLC | $11.60 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Obiamaka Mora listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.